Evidence map›Paper›PMID 32366119›Full record

ReviewCancer biotherapy & radiopharmaceuticals2020

Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.

Tanya B Dorff, Cy Stein, Marcin Kortylewski, Edwin Posadas, Timothy Synold, David Quinn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biotherapy & radiopharmaceuticals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tanya B DorffDepartment of Medical Oncology and Developmental Therapeutics, City of Hope National Medical Center, Duarte, California, USA.
Cy SteinDepartment of Medical Oncology and Developmental Therapeutics, City of Hope National Medical Center, Duarte, California, USA.
Marcin KortylewskiBeckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Edwin PosadasSamuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Timothy SynoldBeckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
David QuinnDepartment of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
City Of Hope National Medical Center · USCedars-Sinai Medical Center · USUSC Norris Comprehensive Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

The effects of radium-223 on the immune system and the bone tumor microenvironment are incompletely understood. The authors describe mechanisms by which radium-223 may interact with the immune system, specifically through STAT-3 and impact on tumor and circulating lymphocyte populations. They review mechanisms through which effects of radium-223 and androgen-targeted therapy on bone microenvironment could be better elucidated. These knowledge gaps currently limit development of optimal combination therapy approaches for radium-223. Tissue based studies are currently underway in a prospective clinical trial to enhance therapeutic perspective on radium-223 treatment in the prostate cancer landscape.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalBone and BonesBone NeoplasmsChemoradiotherapyHumansMaleProstatic Neoplasms, Castration-ResistantRadiumTreatment OutcomeTumor MicroenvironmentAndrogen AntagonistsAntineoplastic Agents, HormonalRadiumRadium-223bone metastasesimmunogenicityprostate cancerradiopharmaceuticals

Identifiers

PMID32366119
PMCPMC13244925
OpenAlexW3022129765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.